BIVI Share Price | BioVie, Inc. Stock Analysis & Recommendation

Q: How big is BioVie, Inc.?

Market Cap: As of Jun 18, BioVie, Inc. has a market capitalization of 19.13 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24, BioVie, Inc. reported net sales of 0.00 million and a net profit of -18.99 million.Balance Sheet Snapshot: As of Jun'24, the company reported shareholder's funds of 15.51 million and total assets of 25.21 million.

Q: What does BioVie, Inc. do?

Overview:BioVie, Inc. is a clinical-stage company in the Pharmaceuticals & Biotechnology industry, focused on the discovery, development, and commercialization of drug therapies for liver disease.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 19.13 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.06 Return on Equity: -87.15% Price to Book: 0.88Contact Details:Address: 2120 Colorado Ave Ste 230, SANTA MONICA CA: 90404-3559 Tel: 1 310 4444300 Website: http://www.biovieinc.com/

Q: Who are in the management team of BioVie, Inc.?

As of March 2022, the management team of BioVie, Inc. includes Mr. Terren Peizer, who serves as the Chief Executive Officer and Director. Additionally, the Board of Directors comprises Mr. Richard Berman, Mr. Steven Gorlin, Dr. Robert Hariri, Mr. Rajah Menon, and Mr. Sigmund Rogich, all of whom hold the designation of Director.

Q: Is BioVie, Inc. technically bullish or bearish?

As of 31 July 2025, the technical trend for BioVie, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, and the daily moving averages are bearish. The KST shows a bearish stance weekly but is mildly bullish monthly. The OBV is mildly bullish weekly, but there is no trend on the monthly scale. Overall, the indicators suggest a mildly bullish stance, but the bearish signals in the weekly MACD and daily moving averages temper this outlook.In terms of performance, BioVie has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -90.65% versus the S&P 500's 12.22%, highlighting a stark contrast in performance.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

27.01 k

Shareholding (Sep 2025)

FII

0.27%

Held by 15 FIIs

DII

97.81%

Held by 2 DIIs

Promoter

0.00%

How big is BioVie, Inc.?

22-Jun-2025

As of Jun 18, BioVie, Inc. has a market capitalization of 19.13 million and reported net sales of 0.00 million with a net profit of -18.99 million for the latest four quarters. The company has shareholder's funds of 15.51 million and total assets of 25.21 million as of Jun'24.

View full answer

What does BioVie, Inc. do?

22-Jun-2025

BioVie, Inc. is a clinical-stage pharmaceutical company focused on developing drug therapies for liver disease. As of March 2025, it has a market cap of $19.13 million and reported a net profit loss of $3 million.

View full answer

Who are in the management team of BioVie, Inc.?

22-Jun-2025

As of March 2022, the management team of BioVie, Inc. is led by CEO and Director Mr. Terren Peizer, with the Board of Directors including Mr. Richard Berman, Mr. Steven Gorlin, Dr. Robert Hariri, Mr. Rajah Menon, and Mr. Sigmund Rogich.

View full answer

Is BioVie, Inc. technically bullish or bearish?

20-Sep-2025

As of July 31, 2025, BioVie, Inc. shows a mildly bullish trend overall, despite mixed signals from various indicators and a significant year-to-date underperformance of -90.65% compared to the S&P 500's 12.22%.

View full answer

Compare BioVie, Inc. with Similar Stocks

Design Therapeutics, Inc.Trevi Therapeutics, Inc.Vor Biopharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 9 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-74.15%

Price to Book

0.36

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.75%

6 Months

-61.59%

1 Year

-77.78%

2 Years

-98.17%

3 Years

-93.94%

4 Years

-99.29%

5 Years

-99.08%

BioVie, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-236.38%

EBIT to Interest (avg)

-33.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.06

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

3.49%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.92

EV to EBIT

0.16

EV to EBITDA

0.16

EV to Capital Employed

2.39

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1519.24%

ROE (Latest)

-87.15%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 10 Schemes (1.92%)

Foreign Institutions

Held by 15 Foreign Institutions (0.27%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 28.57% vs 46.15% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-4.70",
          "chgp": "23.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.50",
          "val2": "-4.90",
          "chgp": "28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 45.48% vs 36.18% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.80",
          "val2": "-32.00",
          "chgp": "44.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "2.90",
          "chgp": "-89.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.50",
          "val2": "-32.10",
          "chgp": "45.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.60

-4.70

23.40%

Interest

0.00

0.40

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-3.50

-4.90

28.57%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 28.57% vs 46.15% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-17.80

-32.00

44.38%

Interest

0.30

2.90

-89.66%

Exceptional Items

0.00

1.80

-100.00%

Consolidate Net Profit

-17.50

-32.10

45.48%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 45.48% vs 36.18% in Jun 2024

All Annual Results

Company CV

About BioVie, Inc.

BioVie, Inc.

Pharmaceuticals & Biotechnology

BioVie Inc clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company has developed a new drug candidate, BIV201 (continuous infusion terlipressin) and has completed a mid-stage Phase IIa clinical trial for treating ascites due to advanced liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The initial target for BIV201 therapy is refractory ascites, a serious complication of liver cirrhosis with an estimated 50% mortality rate within six to 12 months.

Company Coordinates

Company Details

2120 Colorado Ave Ste 230 , SANTA MONICA CA : 90404-3559

Tel: 1 310 4444300

http://www.biovieinc.com/

Registrar Details

BioVie, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is BioVie, Inc.?

Watch in Real-Time

What does BioVie, Inc. do?

Who are in the management team of BioVie, Inc.?

Is BioVie, Inc. technically bullish or bearish?

Compare BioVie, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Jun'25

About BioVie, Inc.

Company Coordinates